Aethlon medical announces u.s. fda approval of hemopurifier covid-19 study protocol amendment

Approval eliminates the requirement for previous dialysis treatment, potentially enabling accelerated enrollment in the ongoing clinical study san diego , july 11, 2022 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that the u.s. food and drug administration (fda) has approved an amendment to the protocol of its ongoing clinical trial investigating the aethlon hemopurifier® for patients with severe covid-19. the newly approved protocol amendment eliminates the inclusion criteria that patients must have a dialysis catheter in place and have tolerated dialysis at the time of screening.
AEMD Ratings Summary
AEMD Quant Ranking